The capacity of the adult brain to self-regenerate upon injury is limited. Replacement of neurons only takes place in a few spatially restricted neurogenic regions, where neural stem cells retain fate plasticity [the subventricular zone and the subgranular zone of the dentate gyrus in rodents, the adult human hippocampus and striatum; reviewed in (11) ]. Outside these neurogenic regions, proliferating NG2 glia precursors are the endogenous source of cells with multipotent potential (12, 13) , but they remain glialrestricted in situ. Hence, most of the brain consists of nonneurogenic regions apparently incapable of repair. The knowledge gained from neurogenic niches can be used to drive cell fate of (non-neurogenic) resident progenitor cells. Previous in vivo work in rodents has provided insights into initiation of adult neurogenesis in models of targeted apoptotic cell death (14, 15) , as well as after acute brain injury (stab lesion) (16, 17) . Although the goal of generating new neurons from endogenous precursor cells was achieved, these approaches required specific forms of tissue damage. However, non-selective injury, as in the case of traumatic brain injury, never, or in the case of brain ischemia, barely (18) leads to endogenous neuronal cell birth.
Direct in vivo reprogramming into the desired phenotype 'Direct reprogramming' has become a popular approach to induce a neuronal fate. Direct reprogramming of somatic cells into pluripotent stem cells in vitro (19) has opened up entirely new possibilities in regeneration research. Successful direct in vivo reprogramming of desired tissuespecific cells was achieved in the pancreas (20) and myocardium (21) . Recent research has refined technologies to induce neurogenesis using gene therapy. In the adult brain, gene delivery and lineage tracing approaches were used to create a neurogenic niche and to drive cell fate in vivo. Using one of the several factors studied [e.g., BDNF, Sox2, Pax6, Olig2, achaete-scute complex homologlike 1 (Ascl1), Bcl-2], cell genesis or enlargement of the progenitor cell pool was accomplished in neurogenic niches and following stroke. It has been shown that selectively modifying transcriptional cues is sufficient to induce a cell fate switch in the dentate gyrus neurogenic niche and striatum: e.g., conversion of neural stem/progenitor cells into oligodendrocytes by Ascl1, also known as Mash1 (22) ; enlargement of the pool of glia cells that may support a cell-replacement strategy aimed at remyelination after injury (23); reprogramming of striatal astrocytes into neuroblasts by viral-mediated expression of Sox2 (24) ; and retroviral delivery of the lineage-instruction factors Olig2 and Pax6 altering the neurogenesis-gliogenesis ratio (25) . Although retroviral overexpression of the pro-neuronal factor Pax6 pushes precursor cells in the dentate gyrus into a neuronal phenotype, survival of these engineered cells is significantly reduced (25) . In models of mild cerebral ischemia, induced cell death was delayed by altering cell cycle regulatory mechanisms (26) , and gene delivery of fate determinants induced the birth of immature neurons in the non-neurogenic injured striatum (18) . Newly generated cells after brain injury or stroke were identified by coexpression of the thymidine analog bromodeoxyuridine (BrdU) and doublecortin. Known as a marker of immature neurons in neurogenic regions, doublecortin has distinctive characteristics dependent on the niche environment (27) .
Altogether, only few (typically immature) cells are generated upon viral gene delivery of fate determinants. Furthermore, bona fide neurons commonly identified by co-expression of BrdU and the neuronal nuclear marker NeuN may possibly represent an artifact (28) . Indeed, aberrant DNA synthesis may lead to incorporation of BrdU and, thus, may indicate the induction of cell death rather than the birth of a new neuron (26, 28) . Another challenge besides ectopic induction of neurogenesis is to generate neurons that become functionally integrated. So far, these efforts have met with limited success, although resident glia cells have been shown to differentiate into spiking neuroblasts in models of stroke (18, 29) . Cleary, outside the canonical neurogenic brain region, newly generated immature neurons lack crucial signals within the nonneurogenic and injured region. The niche environment therefore needs to be primed as well for neuronal fate conversion and subsequent neuronal differentiation, which, in turn, requires coordinated and cell type-specific transcription of the genes involved alongside the release of neurotrophic factors to foster a pro-neurogenic milieu.
Taken together, the existing literature suggest that driving neurogenesis de novo from stem/progenitor cells in vivo has its downsides as it often leads to cell death, disruption of homeostasis within the niche, and not to the desired recovery of the region. In their study, Magdalena Goetz and co-workers define cell death as the 'main limiting factor of neuronal reprogramming' and study coordinated metabolic reprogramming at the time of cell fate transition. At this 'metabolic checkpoint', key neuronal genes are rapidly regulated leading to either cell death or survival. Gascón et al. made use of the highly advanced method of continuous single-cell imaging to track fate conversion of (I) Ascl1-transfected astrocytes and (II) after brain injury in vivo. Thereby, the focus of their study was on metabolic features common to all cell types that may improve cellular reprogramming (1) .
Redox homeostasis in neuronal reprogramming
Reactive oxygen species (ROS) production, lipid peroxidation, or cell death-regulating proteins such as Bcl-2 are emerging as potent contributors to cell death or survival decisions. Redox homeostasis, the interplay of oxidative stress and antioxidant signaling (30) , is a biological feature common to all cell types. It marks a metabolic interface for intrinsic vs. environmental signals and can command cell death programs. At neuronal fate conversion, reprogramming from glycolytic to oxidative metabolism formidably challenges redox homeostasis. High oxidation levels lead to apoptosis or ferroptosis (an oxidative stress-dependent/caspase-independent form of cell death characterized by accumulation of lipid peroxidation products), thereby limiting the number of cells adopting a neuronal phenotype. This finding may not come as a big surprise to researchers at the bench, as we already know from daily cell culture work that neuronal progenitors almost literally hate oxidation. In the study by Gascón and co-workers, treatment with liproxstatin-1, a ferroptosis inhibitor, was shown to not only prevent cell death but also to improve reprogramming efficiency. This was accompanied by suppression of ROS production and lipid peroxidation, leading to increased survival of new neurons. Another efficient molecule to reduce lipid peroxidation is forskolin. When added to Ascl1-transduced astrocytes, a cell type-independent increase in fate transition was observed which Nrf2 anti-oxidative pathways supported (1) .
Yet another regulator of the metabolic switch is the anti-apoptotic protein Bcl-2 which improves metabolic conversion at the time of direct neuronal reprogramming. In their report, Magdalena Goetz and coworkers demonstrate that Bcl-2 co-expression in Ascl1-transfected astroglia cells facilitates neuronal conversion in tandem with increased cell survival via the non-canonical pathway (Bcl-2 inhibits apoptosis by sequestering Bax/Bak when phosphorylated at serine 69/70) (1) . Thereby, Bcl-2 improves maturation uncoupled from cell proliferation leading to successful neuronal transition: up to 80% of Ascl1-transduced astrocytes turned into neurons upon Bcl-2 (1). Furthermore, both Bcl-2 and forskolin together enhanced conversion efficiency in the presence of neuronal fate determinants (e.g., Neurog2) (1) .
So far, the replenishment of neuronal populations in the injured brain has fallen short both in quantity and in quality. The oxidative stress response along with lipid peroxidation plays a key role in directed reprogramming as shown in vitro (1) . In situ, injury profoundly affects the niche environment inducing inflammation and thereby shifting redox homeostasis. Previous in vivo work by the same group had already provided invaluable insights into initiation of adult neurogenesis in the injured brain (16, 17) . Here, the authors followed up on their previous experiments and tested whether Bcl-2 and forskolin are capable of enhancing neuronal transition after acute stab wound injury. Excitingly, retroviral gene delivery and singe-cell imaging revealed that direct reprogramming of resident cortical progenitor cells with Bcl-2 (in the presence of the fate determinant Neurog2) increased neuronal conversion and accelerated neuronal maturation at 10 days post-injection. Importantly, two-thirds of transduced cells in vivo were shown to express mature neuronal marker NeuN (1) .
Intriguingly, co-transfection with another anti-oxidant and 'top transcriptional regulator', calcitriol receptor (a.k.a., vitamin D receptor), further improved neuron transition and complexity. Calcitriol-dependent anti-oxidant signaling protected against lipid peroxidation by a mechanism that was independent of mitochondria (1). This exciting discovery raises questions on whether vitamin D itself may also increase cell survival or whether it acts indirectly, for example, via inhibition of the immune system.
In conclusion, the new findings by Gascón and coworkers will have a profound impact on regeneration research by taking the field a huge step forward toward increasing the pool of newly generated neurons. Firm control of metabolic reprogramming in concert with refined timing of genetic factors involved in neuronal fate choice offers great promise for the repair of the injured brain.
